Cargando…
L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to Mycobacterium tuberculosis in a Diabetic Mouse Model
Both active tuberculosis (TB) and asymptomatic latent Mycobacterium tuberculosis (M. tb) infection (LTBI) cause significant health burdens to humans worldwide. Individuals with immunocompromising health conditions, such as Type 2 Diabetes Mellitus (T2DM), have a weakened ability to control M. tb inf...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263396/ https://www.ncbi.nlm.nih.gov/pubmed/35814213 http://dx.doi.org/10.3389/fphar.2022.879729 |
_version_ | 1784742727010746368 |
---|---|
author | Beever, Abrianna Kachour, Nala Owens, James Sasaninia, Kayvan Kolloli, Afsal Kumar, Ranjeet Ramasamy, Santhamani Sisliyan, Christina Khamas, Wael Subbian, Selvakumar Venketaraman, Vishwanath |
author_facet | Beever, Abrianna Kachour, Nala Owens, James Sasaninia, Kayvan Kolloli, Afsal Kumar, Ranjeet Ramasamy, Santhamani Sisliyan, Christina Khamas, Wael Subbian, Selvakumar Venketaraman, Vishwanath |
author_sort | Beever, Abrianna |
collection | PubMed |
description | Both active tuberculosis (TB) and asymptomatic latent Mycobacterium tuberculosis (M. tb) infection (LTBI) cause significant health burdens to humans worldwide. Individuals with immunocompromising health conditions, such as Type 2 Diabetes Mellitus (T2DM), have a weakened ability to control M. tb infection and are more susceptible to reactivation of LTBI to active diseases. T2DM cases are known to have glutathione (GSH) deficiency and impaired immune cell function, including the granulomatous response to M. tb infection. We have previously reported that liposomal glutathione (L-GSH) supplementation can restore the immune cell effector responses of T2DM cases. However, the effects of L-GSH supplementation on the bactericidal activities of first-line anti-TB drug rifampicin (RIF) against M. tb infection have yet to be explored. The aim of this study is to elucidate the effects of L-GSH supplementation in conjunction with RIF treatment during an active M. tb infection in a diabetic mouse model. In this study, we evaluated total and reduced levels of GSH, cytokine profiles, malondialdehyde (MDA) levels, M. tb burden, and granulomatous response in the lungs. We show that L-GSH supplementation caused a significant reduction in M. tb burden in the lungs, decreased oxidative stress, and increased the production of IFN-γ, TNF-α, IL-17, IL-10, and TGF-β1compared to the untreated mice. In addition, L-GSH supplementation in conjunction with RIF treatment achieved better control of M. tb infection in the lungs and significantly reduced the levels of oxidative stress compared to treatment with RIF alone. Moreover, L-GSH in conjunction with RIF significantly increased TGF-β1 levels compared to treatment with RIF alone. These findings suggest potential therapeutic benefits of L-GSH supplementation in conjunction with first-line antibiotic therapy against M. tb infection in individuals with T2DM. |
format | Online Article Text |
id | pubmed-9263396 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92633962022-07-09 L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to Mycobacterium tuberculosis in a Diabetic Mouse Model Beever, Abrianna Kachour, Nala Owens, James Sasaninia, Kayvan Kolloli, Afsal Kumar, Ranjeet Ramasamy, Santhamani Sisliyan, Christina Khamas, Wael Subbian, Selvakumar Venketaraman, Vishwanath Front Pharmacol Pharmacology Both active tuberculosis (TB) and asymptomatic latent Mycobacterium tuberculosis (M. tb) infection (LTBI) cause significant health burdens to humans worldwide. Individuals with immunocompromising health conditions, such as Type 2 Diabetes Mellitus (T2DM), have a weakened ability to control M. tb infection and are more susceptible to reactivation of LTBI to active diseases. T2DM cases are known to have glutathione (GSH) deficiency and impaired immune cell function, including the granulomatous response to M. tb infection. We have previously reported that liposomal glutathione (L-GSH) supplementation can restore the immune cell effector responses of T2DM cases. However, the effects of L-GSH supplementation on the bactericidal activities of first-line anti-TB drug rifampicin (RIF) against M. tb infection have yet to be explored. The aim of this study is to elucidate the effects of L-GSH supplementation in conjunction with RIF treatment during an active M. tb infection in a diabetic mouse model. In this study, we evaluated total and reduced levels of GSH, cytokine profiles, malondialdehyde (MDA) levels, M. tb burden, and granulomatous response in the lungs. We show that L-GSH supplementation caused a significant reduction in M. tb burden in the lungs, decreased oxidative stress, and increased the production of IFN-γ, TNF-α, IL-17, IL-10, and TGF-β1compared to the untreated mice. In addition, L-GSH supplementation in conjunction with RIF treatment achieved better control of M. tb infection in the lungs and significantly reduced the levels of oxidative stress compared to treatment with RIF alone. Moreover, L-GSH in conjunction with RIF significantly increased TGF-β1 levels compared to treatment with RIF alone. These findings suggest potential therapeutic benefits of L-GSH supplementation in conjunction with first-line antibiotic therapy against M. tb infection in individuals with T2DM. Frontiers Media S.A. 2022-06-24 /pmc/articles/PMC9263396/ /pubmed/35814213 http://dx.doi.org/10.3389/fphar.2022.879729 Text en Copyright © 2022 Beever, Kachour, Owens, Sasaninia, Kolloli, Kumar, Ramasamy, Sisliyan, Khamas, Subbian and Venketaraman. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Beever, Abrianna Kachour, Nala Owens, James Sasaninia, Kayvan Kolloli, Afsal Kumar, Ranjeet Ramasamy, Santhamani Sisliyan, Christina Khamas, Wael Subbian, Selvakumar Venketaraman, Vishwanath L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to Mycobacterium tuberculosis in a Diabetic Mouse Model |
title | L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to Mycobacterium tuberculosis in a Diabetic Mouse Model |
title_full | L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to Mycobacterium tuberculosis in a Diabetic Mouse Model |
title_fullStr | L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to Mycobacterium tuberculosis in a Diabetic Mouse Model |
title_full_unstemmed | L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to Mycobacterium tuberculosis in a Diabetic Mouse Model |
title_short | L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to Mycobacterium tuberculosis in a Diabetic Mouse Model |
title_sort | l-gsh supplementation in conjunction with rifampicin augments the treatment response to mycobacterium tuberculosis in a diabetic mouse model |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263396/ https://www.ncbi.nlm.nih.gov/pubmed/35814213 http://dx.doi.org/10.3389/fphar.2022.879729 |
work_keys_str_mv | AT beeverabrianna lgshsupplementationinconjunctionwithrifampicinaugmentsthetreatmentresponsetomycobacteriumtuberculosisinadiabeticmousemodel AT kachournala lgshsupplementationinconjunctionwithrifampicinaugmentsthetreatmentresponsetomycobacteriumtuberculosisinadiabeticmousemodel AT owensjames lgshsupplementationinconjunctionwithrifampicinaugmentsthetreatmentresponsetomycobacteriumtuberculosisinadiabeticmousemodel AT sasaniniakayvan lgshsupplementationinconjunctionwithrifampicinaugmentsthetreatmentresponsetomycobacteriumtuberculosisinadiabeticmousemodel AT kolloliafsal lgshsupplementationinconjunctionwithrifampicinaugmentsthetreatmentresponsetomycobacteriumtuberculosisinadiabeticmousemodel AT kumarranjeet lgshsupplementationinconjunctionwithrifampicinaugmentsthetreatmentresponsetomycobacteriumtuberculosisinadiabeticmousemodel AT ramasamysanthamani lgshsupplementationinconjunctionwithrifampicinaugmentsthetreatmentresponsetomycobacteriumtuberculosisinadiabeticmousemodel AT sisliyanchristina lgshsupplementationinconjunctionwithrifampicinaugmentsthetreatmentresponsetomycobacteriumtuberculosisinadiabeticmousemodel AT khamaswael lgshsupplementationinconjunctionwithrifampicinaugmentsthetreatmentresponsetomycobacteriumtuberculosisinadiabeticmousemodel AT subbianselvakumar lgshsupplementationinconjunctionwithrifampicinaugmentsthetreatmentresponsetomycobacteriumtuberculosisinadiabeticmousemodel AT venketaramanvishwanath lgshsupplementationinconjunctionwithrifampicinaugmentsthetreatmentresponsetomycobacteriumtuberculosisinadiabeticmousemodel |